about
Genetic risk and behavioural changeAlcohol, nicotine, caffeine, and mental disordersPharmacogenetics, pharmacogenomics and airway diseaseIs there evidence for potential harm of electronic cigarette use in pregnancy?Genetic matters: thirty years of progress using mouse models in nicotinic research.Predictors of the nicotine reinforcement threshold, compensation, and elasticity of demand in a rodent model of nicotine reduction policy.The genetics of tobacco use: methods, findings and policy implicationsGenotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidasePolymorphisms of CYP2A6 and its practical consequencesNovel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer RiskSymbiotic relationship of pharmacogenetics and drugs of abuse.A research agenda for assessing the potential contribution of genomic medicine to tobacco control.Personality, behavior and environmental features associated with OXTR genetic variants in British mothers.Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning.Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction.Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey.Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis.Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression.Rapid detection of the CYP2A6*12 hybrid allele by Pyrosequencing technology.Abuse liability assessment of tobacco products including potential reduced exposure productsPolymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancerMicroplate array diagonal gel electrophoresis for mutation research in DNA banks.Cigarette smoking.The genetics of nicotine dependence: relationship to pancreatic cancer.Co-morbidity of smoking in patients with psychiatric and substance use disorders.Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers.A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descentAssociation between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers.'Smoking genes': a genetic association study.Single nucleotide polymorphisms and the future of genetic epidemiology.Nicotinic acetylcholine receptor variants are related to smoking habits, but not directly to COPD.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Candidate gene case-control association studies: advantages and potential pitfalls.Pharmacogenetic Optimization of Smoking Cessation Treatment.Genetic testing: the future of smoking cessation therapy?The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.Treatment of tobacco dependence: integrating recent progress into practice.Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.Applying genetic approaches to the treatment of nicotine dependence.
P2860
Q24525204-8238EFF2-16F7-4534-BCBD-2121FF5DBF64Q24635635-492D8820-0E7B-400F-A746-66F6F191ECC0Q24798917-CD98DC81-E95A-4B20-B0BE-9ACB3F58CC37Q26830532-6B7CC88B-C0E5-429D-BFC0-297557C506F4Q26853457-9BFFE392-F52A-4183-99B5-FA9DFE9EC445Q27312260-544E0482-B7A3-40D6-994F-4E5AAF29CF29Q28201220-88E64A6A-4DB5-4E58-A84C-C96DBBC7CEDFQ28289652-07CE78F2-3806-46B2-B08A-9DF4F0B8A661Q28362536-A8A0EF86-B803-4D97-8CCA-427E7C9ACA81Q28390824-1ECB99DC-4DFE-4C4B-8DEF-5E7588CDF83FQ28476270-789C6611-7797-40D0-A6EF-01A556C55E5EQ30230101-469F0441-B27C-4511-A3CE-3483415FF0EDQ30414325-167AB37E-6C93-4A5D-A0B5-4BBE6E8A99AEQ30448530-5D2FA984-8D9B-4E0F-8783-907DB13BB7D4Q30491854-CA9ED372-A7FA-472D-8BC0-536ABB368892Q32034593-67DB2D83-657E-4874-AEE6-2D14795A12D5Q32160224-EEA23AB7-F915-4169-9CAE-DE8A43DD541CQ33224655-4D8CBC9A-4A6A-4041-8790-B3766AB3A392Q33455775-1D682EAF-B52E-4A17-954D-20C0268DD480Q33496353-C4A121B5-C13A-4861-8742-55807B159A28Q33559301-81E25FA2-7F20-47EC-84B7-88945595A244Q33608783-DFA67584-54BA-4A15-A5D8-57E8E1265843Q33669236-1A88FBBB-373E-494E-A4CF-9DD76CBCA4E8Q33713902-BE58979C-3FF0-4788-99AF-3FDF27D4AE7EQ33866866-07967B7E-CAB1-4784-9BC0-201AEB4C5211Q33942653-09AAB90F-E7C4-4AFD-AA3D-052DB5EA17F1Q33968942-45BD839B-F561-4F6D-90A8-3B878A2D7AFBQ34020315-EDE330F2-336F-48AE-BB23-E1B5AC953E26Q34028131-827E76C4-5930-438A-A235-012CAA9D277AQ34064582-24A959B9-8F9A-4F73-941A-1795F774391EQ34081504-D67A3C47-B04B-44A5-A343-18CA611CE961Q34206203-51132DB1-C256-43AE-8B6C-B3998433B440Q34430456-28C2CA75-46A1-46B1-80CC-53D5F2C2D75BQ34459045-B07041AD-8DD4-48F7-9BB1-D54D56871538Q34542169-84E32E19-27C3-4605-82B4-D10073AE5CEDQ34606970-65982CE8-9AEF-4360-8EAD-C350453E4D91Q34612112-A07770FD-246F-4A51-8DB0-28D6742A00A9Q34715360-1367931E-2010-4203-A1EB-EACF54133424Q34926339-39D1AFAD-5855-46C1-8549-EA66C63EC2FFQ34963561-F9C0C13F-74BF-49F8-82E2-AB17436D04B3
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Nicotine metabolism defect reduces smoking.
@en
Nicotine metabolism defect reduces smoking.
@nl
type
label
Nicotine metabolism defect reduces smoking.
@en
Nicotine metabolism defect reduces smoking.
@nl
prefLabel
Nicotine metabolism defect reduces smoking.
@en
Nicotine metabolism defect reduces smoking.
@nl
P356
P1433
P1476
Nicotine metabolism defect reduces smoking.
@en
P2093
M L Pianezza
R F Tyndale
P2888
P356
10.1038/31623
P407
P577
1998-06-01T00:00:00Z
P6179
1052691214